We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dyadic -- Ignore unavailable to you. Want to Upgrade?

To: Paul Lee who wrote (7)2/27/2018 8:46:56 AM
From: Paul Lee  Respond to of 9
Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1
GlobeNewswire•February 27, 2018
JUPITER, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) ( DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications with Mitsubishi Tanabe Pharma Corp., one of the World’s top tier pharmaceutical companies.

“We are very pleased to have the opportunity to collaborate with Mitsubishi Tanabe Pharma Corp. to express two of its important therapeutic compounds using our C1 production platform”, said Mark Emalfarb, Dyadic’s CEO. “This research and development program is aiming to help Mitsubishi Tanabe overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based biologics because of its speed of development and low cost of goods.”

“In this research collaboration, we will be using our proprietary synthetic biology and genome engineering techniques to further modify our C1 host production organism to produce the desired therapeutic proteins”, said Ronen Tchelet, Ph.D., Dyadic’s Head of Research. “We have already proved that our C1 technology is capable of speeding up the development process and producing certain monoclonal antibodies (mAbs) at commercially important levels. We expect this project to generate additional data and to enlarge the diversity of the types of proteins that our C1 platform can potentially produce at higher yields and with lower cost.”

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, the Company has entered into a proof of concept research project to explore the potential of its C1 technology to produce an important active moiety for a third party. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of using these technologies in the development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines & drugs to market faster, in greater volumes, at lower cost, and potentially with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.